Impact of Cannabis Consumption on the Course, Modalities of Hospitalization and the Short-term Prognosis of Inpatients Suffering From Psychotic Symptoms

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCentre hospitalier de Ville-Evrard, France

About this trial

Few studies have evaluated, in patients with symptomatology the impact of cannabis use on the duration of hospitalization and on short- and medium-term developments. The objective of this study will be to assess the impact of cannabis on the duration, the hospitalization and the short- and medium-term evolution of patients with psychotic symptoms and cannabis use. We hypothesize that these patients (in comparison with patients with psychotic symptomatology and not using cannabis) would be hospitalized more long, exposed to a higher risk of resistance to the usual therapeutics, would have a lack of therapeutic alliance and insight, relapses and hospitalizations more frequent, more marked negative symptoms and lower quality remission. They would also be more prone to impulsive and aggressive behaviour.

Eligibility criteria

Qualifiers

Hospitalized in psychiatry regardless of the mode of hospitalization

With or without protective measures (guardianship or curatorship)

Presenting psychotic symptoms (schizophrenia, schizo affective disorder, thymic disorder with psychotic characteristic, psychotic disorder substance-induced, brief psychotic disorder, schizophrenic disorders, delirious disorders)

Members of the social security system

Disqualifiers

Degenerative neurological pathologies or mental retardation

Psychotic disorders secondary to generalized medical conditions(epilepsy, delirium tremens, tumors, etc.)

Other psychiatric pathologies

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed